Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Cancer cell (direct lysis)" refers to the process by which immune effector cells—primarily cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells—directly induce the death of cancer cells through lytic mechanisms. This involves granule-mediated cytotoxicity (perforin/granzyme) and death receptor-mediated cytotoxicity (FasL/FasR, TRAIL/TRAIL-R). It is a fundamental aspect of immune surveillance and immunotherapy, where the goal is to eliminate malignant cells via direct cytotoxicity.
Direct lysis of cancer cells through granule-mediated cytotoxicity (perforin/granzyme) and death receptor-mediated cytotoxicity (FasL/FasR, TRAIL/TRAIL-R).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cancer Cell (Direct Lysis).